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Background. Hepatic lymph node involvement is generally considered a contraindication for liver resection performed for colorec-
tal liver metastases. However, some advocate hepatic lymphadenectomy in the presence of macroscopic involvement and others
routine lymphadenectomy. The aim of this review is to assess the role of lymphadenectomy in resection of liver metastases from
colorectal cancer. Methods. Medline, Embase and Central databases were searched using a formal search strategy. Trials with sur-
vival data with a minimum follow-up of 1 year were considered for inclusion. Meta-analysis was performed using Revman. Results.
A total of 4230 references were identiﬁed. Ten reports of nine studies including 926 patients qualiﬁed for the review. The preva-
lence of nodal metastases after routine lymphadenectomy was 16.3%. The overall 3-year and 5-year survival rates in node-positive
patients were 9/151 (11.3%) and 2/137 (1.5%), respectively, compared to 3-year and 5-year survival rates of 424/787 (53.9%) and
246/767 (32.1%) in node-negative patients. The odds ratios for 3-year and 5-year survivals in node positive disease compared
to node-negative disease were 0.12 (95% CI 0.06 to 0.24) and 0.08 (95% CI 0.03 to 0.22). There was no randomized controlled
trial which assessed the survival beneﬁt of routine or “selective” lymphadenectomy. Conclusion. Currently, there is no evidence of
survival beneﬁt for routine or selective lymphadenectomy. Survival rates are low in patients with positive lymph nodes draining
the liver irrespective of whether they are detected by routine lymphadenectomy or by macroscopic involvement. Further trials in
this patient group are required.
Copyright © 2008 Kurinchi S. Gurusamy et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. BACKGROUND
Colorectal cancer is the third commonest malignancy in the
United Kingdom with an estimated 34000 cases diagnosed
every year [1]. In men, it is next only to prostatic and lung
cancer and has an incidence of 53.8 per 100000 population
[1]; in women, it is next only to breast and lung cancers and
has an incidence of 34 per 100000 population [1].
It is the second most common cause of cancer mortality
(next only to lung cancer) accounting for nearly a tenth of
cancerdeathsinUK[1]andfor1in40deathsfromallcauses
[1, 2]. Nearly 16000 people die annually due to colorectal
cancer [1].
Liver is the commonest site of recurrence in people who
undergo curative surgery for colorectal cancer [3, 4] and 20–
32% of these metastatic deposits are respectable [4–6]. The
5-year survival after liver resection varies between 16% and
30% [5, 7–10]. The tumour recurrence rate after resection of
hepatic metastases varies between 40.4% and 73.5% [11, 12].
The common sites of recurrence include liver, lung, peri-
toneum, and locoregional recurrence [12].
Involvement of hepatic lymph nodes during liver resec-
tion is considered as a poor prognostic factor [13, 14], with
5-year survival rate after liver resection varying between 0
and 4.3% [8, 15, 16]. In people with positive nodes, after ad-
justing for diﬀerent factors such as tumour number [8, 16–
18],size[16–18],distribution[16,17],andsurgicalresection
margin [18], survival rates after liver resection are similar
to those in patients with unresectable colorectal metastasis
whounderwenthepaticinfusionchemotherapy[19,20].Me-
dian survival after systemic chemotherapy with leukovorin,
5-ﬂuorouracil, oxaliplatin, and irinotecan has been recently
reported to be around 20 months [21, 22] with an estimated
3-year survival of about 10% [22]. In light of this, hepatic2 HPB Surgery
nodeinvolvementdetectedpre-operativelyorduringsurgery
is generally considered a contra indication for liver resection
for liver secondaries from colorectal primary [23, 24]. Al-
though the surgical technique in the treatment of colorec-
tal liver metastases has undergone few modiﬁcations, with
theimprovingresultsofresectionofextra-hepaticdisease(5-
year survival of 18%) following neo-adjuvant chemotherapy
[6], hepatic node involvement as a contra indication for liver
resection for colorectal liver metastases requires to be recon-
sidered.
In patients with liver metastases, about 14% to 15% of
nodes(drainingtheliver)considereduninvolvedmacroscop-
ically are inﬁltrated by tumour cells microscopically [15, 16].
Patients who have involvement of common hepatic artery
nodesandcoeliacarterynodes(consideredasgroup2nodes)
[25] have been reported to have a poorer prognosis than
the patients with involvement of hepato-duodenal or retro-
pancreatic group of nodes (considered as group 1 nodes)
[25]. Approximately half of the microscopic disease is in the
hepato-duodenal and the retro-pancreatic group [25]a n d
therefore amenable to radical lymphadenectomy. The mech-
anism for development of hepatic node involvement is not
known nor whether they represent spread from the liver
metastases [8] or the primary bowel cancer.
In the absence of clear beneﬁcial eﬀects of adjuvant
chemotherapy in potentially curative liver resections for
colorectal liver metastases [26], the practice of adjuvant
chemotherapy is varied. While some surgeons use adjuvant
chemotherapy after all resections [27, 28], others use adju-
vant chemotherapy only in patients with poor prognostic
factors [29]. The potential advantage of performing routine
hepatic lymphadenectomy at the time of liver resection for
colorectal metastases is the removal of the microscopically
involved lymph nodes and to provide adjuvant chemother-
apy in patients who do not have other poor prognostic fac-
tors.
The primary aims of this review are to determine the
role of routine lymphadenectomy or lymphadenectomy in-
dicated by macroscopic nodal involvement; to determine the
prognostic signiﬁcance of hepatic lymph node status in pa-
tients undergoing liver resection for colorectal metastases;
andwhetherliverresectionisindicatedinpatientswithnodal
involvement. The secondary aim is to determine if the extent
of lymphadenectomy aﬀects prognosis.
A systematic review of the literature on hepatic lymph
node involvement in colorectal metastases was published in
2000 [13]. However, in the last 6 years, there have been sig-
niﬁcant advancements in the treatment of liver metastases
including neo-adjuvant chemotherapy [6] and further liter-
ature analysis was therefore indicated.
2. METHODS
2.1. Searchstrategy
The following databases were searched: Medline (January
1990–January 2006), Embase (January 1990–January 2006),
and Central (Issue 1, 2006 from 1990). The following search
strategy was used: (“Neoplasm Metastasis” [MeSH] OR
metasta∗ OR secondar∗ OR spread OR cancer OR carci-
noma OR tumour Or tumor OR neoplasm) AND (colon Or
colonic OR colorect∗ ORrectalORrectumORgutORintes-
tineORbowelOR“Intestine,Large”[MeSH]OR“Colorectal
Surgery”[MeSH]OR“IntestinalNeoplasms” [MeSH])AND
((“Liver” [MeSH] OR “Liver Neoplasms” [MeSH] OR “Liver
Diseases” [MeSH] OR liver OR hepatic) AND (segmentec-
tomy OR resection) OR “Hepatectomy” [MeSH]) AND “hu-
mans” [MeSH Terms] AND English [Lang] AND (“1990”
[PDAT] : “3000” [PDAT]).
Equivalent search strategies were used in the Embase and
Central.
2.2. Inclusionandexclusioncriteria
The following studies were included: randomized controlled
trials; comparative series; published in journals January 1990
onwards; full text in English language; should have survival
or cancer recurrence data; and a minimum duration of fol-
l o wu po fo n ey e a r .
The following studies were excluded: number of patients
undergoing liver resections <10; includes liver resection for
other cancers (primary or secondary); includes repeat or
multistaged liver resections; includes combined excision of
liver and lung metastases; hepatic lymph-node status not re-
ported;mentionofextrahepaticdiseasebutnotclearlystated
as hepatic lymph nodes; mention of regional lymph nodes
but not clear whether the lymph nodes drain the primary tu-
mour or the secondary tumour; not possible to identify the
survival or recurrence data for hilar node-positive and nega-
tivestatusseparately;nocontrols(e.g.,survivalreportedonly
in node-negative disease and node-positive diseases did not
undergo resection); lost to follow up >10%.
The following outcomes were measured: in-hospital
mortality/surgical mortality/30-day mortality; 1-, 3-, and 5-
year survival; 1-, 3-, and 5-year disease-free survival; mean
time to recurrence (mean disease free survival).
2.3. Dataextracted
The following data were extracted from each study using a
custom-designed data extraction form: year of publication;
year of study; country of study; type of study; population
characteristics such as age, gender ratio; inclusion and ex-
clusion criteria used in individual studies; number of indi-
viduals entering the study; follow-up period; lost to follow
up; tests performed during follow-up period; hepatic lymph
node involvement and how it was diagnosed; any adjuvant
therapy (including neo-adjuvant therapy)—indication and
details; whether routine hepatic lymphadenectomy was per-
formed; operating time; blood loss, number of units trans-
fused;hospitalstay;complicationsofsurgery(directlyrelated
to surgery—such as bleeding, bile leak, intra-abdominal col-
lections etc., and general complications such as pneumo-
nia; cardiac complications, etc.); survival and mortality data;
time to recurrence; type of recurrence (including local or re-
gional or remote in relation to liver and the actual sites of
recurrence); and quality of life measures (however, described
by author).Kurinchi S. Gurusamy et al. 3
2.4. Statisticalmethods
RevMan Analyses 1.0 [30] was used for meta-analysis. The
odds ratio with 95% conﬁdence interval was calculated. The
random-eﬀects model [31] and the ﬁxed-eﬀect model [32]
were used. Subgroup analysis, based on whether the studies
included nodes involved macroscopically or microscopically
was performed. Other subgroup analyses performed were
those based on whether routine lymphadenectomy or selec-
tive lymphadenectomy was performed; whether chemother-
apy was used, whether only the lymph nodes along the hep-
atoduodenal ligament were removed (as compared to the re-
moval of the other groups of nodes mentioned previously)
and whether a localised or radical lymphadenectomy was
performed.
Heterogeneity was explored using the chi-squared test
with signiﬁcance set at P value 0.10 and I2 was used to mea-
sure the quantity of heterogeneity [33]. StatsDirect 2.4.5 [34]
was used for calculating the sample size.
2.5. Deﬁnitionsused
The following deﬁnitions were used in this review.
(i) Disease free survival: patients who are alive and who
have not shown any signs of recurrence of cancer clin-
ically or radiologically.
(ii) Primary site: primary site of origin in the colon or rec-
tum.
(iii) Local recurrence: recurrence at the site of liver resec-
tion. This has no relation to the recurrence of the tu-
mour at the primary site.
(iv) Regional recurrence: peri-hepatic area including porta
hepatis. Again, this has no relation to the regional
lymph nodes draining the primary tumour site.
(v) Remote recurrence: recurrence of cancer in sites not
included in the above two categories. In most cases
(except in hepatic ﬂexure tumours), recurrence at the
primary site will be included in this category.
(vi) Macroscopic lymph node involvement: lymph
node involvement as detected radiologically (pre-
operatively or per-operatively) or by visual and tactile
assessment (Group 3).
(vii) Microscopiclymphnodeinvolvement:lymphnodein-
volvement not detected radiologically (pre-operatively
or per-operatively) or by visual and tactile assessment
but detected by microscopic examination (Group 2).
(viii) Lymph node involvement: macroscopic or micro-
scopic lymph node involvement or both (Group 2 or
Group 3).
(ix) No lymph node involvement: neither macroscopic nor
microscopic lymph node involvement (if assessed)
(Group 1).
(x) Routine lymphadenectomy: lymphadenectomy (of
nodes draining the liver) performed routinely in the
presence or absence of lymph node involvement.
(xi) Hepatic pedicle nodes: nodes along the hepatoduode-
nal ligament, retropancreatic, common hepatic artery,
and coeliac artery.
3. RESULTS
A total of 4230 references through electronic searches of
Pubmed (1895), Embase (2222), and Central, The Cochrane
Central Register of Controlled Trials in The Cochrane Li-
brary (113) were identiﬁed. 1403 duplicate references were
excludedand1958clearlyirrelevantreferenceswereexcluded
through reading titles and abstracts. 869 references were re-
trieved for further assessment. Two more references [35, 36]
were identiﬁed through scanning reference lists of the re-
trieved studies. Out of these, 860 studies were excluded be-
cause of the exclusion criteria. Eleven reports of ten studies
qualiﬁed for the review [7, 8, 15–18, 25, 28, 29, 35, 37]. The
duplicate report [16, 25] was identiﬁed by using the com-
monauthorandcentre.Onestudy,althoughitmettheinclu-
sion criteria, did not provide information for meta-analysis
[17]. Thus, nine studies involving 942 patients were included
for meta-analysis: 151 (16.0%) were node-positive and the
rest were node-negative. There were no randomized con-
trolled trials comparing liver resection alone with liver resec-
tion along with routine lymphadenectomy or lymphadenec-
tomy in those with involved nodes. Similarly, there were no
randomized controlled trials comparing liver resection with
nonsurgical treatments such as chemotherapy in patients
with node-positive disease, who were otherwise suitable for
liver resection.
Thecharacteristicsofincludedstudiesandtheprevalence
of positive nodes in diﬀerent studies are tabulated in Table 1.
Theoverallprevalenceintheincludedstudieswas16.0%and
theprevalencewas16.3%inpatients whounderwentroutine
lymphadenectomy. The prevalence varied from 5.4% to 50%
(see Table 1).
The survival rates of node-positive and node-negative
patients for diﬀerent studies and in diﬀerent categories are
tabulated in Tables 2 and 3. The overall 3-year and 5-year
survivalratesinnode-positivepatientswere11.3%and1.5%,
respectively, compared to 3-year and 5-year survival rates of
53.9% and 32.1% in node-negative patients.
The results of the meta-analysis are tabulated in Table 4.
There was signiﬁcant diﬀerence in the odds of one-year
(Odds ratio 0.11 95% conﬁdence intervals 0.05 to 0.20), 3-
year (OR 0.12 95% CI 0.07 to 0.20), and 5-year survival (OR
0.08 95% CI 0.03 to 0.22) between node-positive and node-
negative groups. The results did not change by adopting the
ﬁxed or random eﬀects model. The forest plot for 3-year sur-
vival is shown in Figure 1. Subgroup analysis was performed
for 3-year and 5-year survival. The odds of survival were sig-
niﬁcantly lower for hepatic node-positive patients compared
to node-negative patients in the diﬀerent subgroup analyses
performed, for example, including studies published before
2000; studies published after 2000; including only studies
with microscopic nodal involvement; only studies in which
chemotherapy was used; and diﬀerent groups classiﬁed by
the extent of dissection. Visual assessment of the funnel plot
did not demonstrate any bias (see Figure 2).4 HPB Surgery
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Table 2: Survival in each study∗.
Study
Node-positive Node-negative
Total One-year
survival
Three-year
survival
Five-year
survival Total One-year
survival
Three-year
survival
Five-year
survival
Nakamura et al.
[28] 6 — 2 (33.3%) — 16 — 10 (62.5%) —
Yasui et al. [35] 8 — 2 (25%) 0 (0%) 56 — 33 (58.9%) 18 (32.1%)
Beckhurts et al.
[8] 35 — 1 (2.9%) 0 (0%) 91 — 44 (48.4%) 20 (22.0%)
Kokudo et al.
[18] 7 6 (85.7%) 2 (28.6%) 0 (0%) 87 84 (96.6%) 57 (65.5%) 47 (54.0%)
Ambiru et al.
[7] 8 — 1 (12.5%) 1 (12.5%) 141 — 63 (44.7%) 38 (27.0%)
Harms et al.
[29] 39 — 1 (2.6%) 0 (0%) 116 — 52 (44.8%) 24 (20.7%)
Sanchez-
Cespedes et al.
[37]
8 2 (25%) 0 (0%) — 7 7 2/4† (50%) —
Jaeck et al.
[16, 25] 17 4 (23.5%) 2 (11.8%) 0 (0%) 143 135 (94.4%) 89 (62.2%) 67 (46.9%)
Laurent et al.
[15] 23 16 (69.6%) 6 (26.1%) 1 (4.3%) 133 117 (88%) 74 (55.6%) 32 (24.1%)
Total 151 28/55
(50.9%)
17/151
(11.3%) 2/137 (1.5%) 790 343/370
(92.7%)
424/787
(53.9%)
246/767
(32.1%)
∗Percentages in brackets; †The follow-up for the other 3 patients was <3y e a r s .
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Figure 1
Only one study [18] reported the disease-free survival
rate. There was no statistically signiﬁcant diﬀerence in the
proportion of node-positive and node-negative patients who
were disease free at one, three, and ﬁve years after liver resec-
tion.Noneofthestudiesreportedonqualityoflifemeasures.
There was no signiﬁcant heterogeneity for the impor-
tant outcomes studied as indicated by the chi-square test, I2
value, and the similar odd’s ratio using the ﬁxed and ran-
dom eﬀects model. The only outcomes with signiﬁcant het-
erogeneity were the one-year survival and the 3-year survival
in the subgroup analysis for routine lymphadenectomy and
chemotherapy.
4. DISCUSSION
The overall prevalence of positive lymph nodes (draining
the liver) was 16.0%. However, the prevalence varied be-
tween 5.4% and 50%. The diﬀerence in the prevalence could
reﬂect the extent of lymphadenectomy. Some surgeons re-
move only the nodes along the hepatoduodenal ligament6 HPB Surgery
Table 3: Survival in each category.
Category Number of studies
Node-positive Node-negative
Total
number
Number
survived
Total
number
Number
survived
Three-year survival
All studies 9 151 17 (11.3%) 787 424
(53.9%)
Studies including microscopic hepatic
node involvement 3 39 8 (20.5%) 193 109
(56.5%)
Studies where routine lymphadenectomy
was performed irrespective of the macro-
scopic nodal status
7 136 15 (11.0%) 696 365
(52.4%)
Studies which involved clearance of peri-
hepatic nodes or hilar nodes only 2 15 2 (13.3%) 91 59 (64.8%)
Studies which involved clearance of nodes
along the hepatoduodenal ligament only
(as opposed to clearance of the retropan-
creatic group, common hepatic artery
group, and celiac group)
3 82 3 (4.7%) 348 160
(46.0%)
Studies which involved clearance of all the
groups of nodes in the hepatic pedicle 4 151 17 (11.3%) 787 424
(53.9%)
Studies in which chemotherapy was used 2 45 3 (6.7%) 132 62 (47.0%)
Studies published before 2000 7 111 9 (8.1%) 511 261
(51.1%)
Studies published after 2000 2 40 8 (20%) 276 163
(59.1%)
Five-year Survival
All studies 7 137 2 (1.5%) 767 246
(32.1%)
Studies including microscopic hepatic
node involvement 2 31 1 (3.2%) 189 50 (26.5%)
Studies where routine lymphadenectomy
was performed irrespective of the macro-
scopic nodal status
6 130 2 (1.5%) 680 199
(29.3%)
Studies which involved clearance of peri-
hepatic nodes or hilar nodes only 1 7 0 (0%) 47 87 (54.0%)
Studies which involved clearance of nodes
along the hepatoduodenal ligament only
(as opposed to clearance of the retropan-
creatic group, common hepatic artery,
group and celiac group)
3 82 1 (1.2%) 348 82 (23.6%)
Studies which involved clearance of all the
groups of nodes in the hepatic pedicle 3 137 2 (1.5%) 767 246
(32.1%)
Studies in which chemotherapy was used 1 39 0 (0%) 116 24 (20.7%)
Studies published before 2000 5 97 1 (1.0%) 491 147
(29.9%)
Studies published after 2000 2 40 1 (2.5%) 276 99 (35.9%)
[7, 8, 29], whilst others remove nodes along the common
hepatic artery, coeliac artery, and the retropancreatic area
[16]. In the study which reported the more extensive lym-
phadenectomy, the prevalence of the nodes along the hep-
atoduodenal ligament and retropancreatic area was 5% and
an additional 5.6% of patients had involvement of the nodes
along the common hepatic artery and coeliac artery. How-
ever, two studies [8, 29] which performed a less-extensive
lymphadenectomy (hepatoduodenal ligament group only)
found a prevalence of greater than 25%. Thus, the extent
of the lymphadenectomy is not the main factor that causes
the diﬀerence in the prevalence rate between studies. Fac-
tors that may inﬂuence the prevalence are patient selection
for surgery, the adequacy of pre-operative staging; whether
nodal macroscopic disease was excluded from the study,
number of nodes examined [37], number of sections perKurinchi S. Gurusamy et al. 7
Table 4: Results of meta-analysis.
Studies included
Number of
studies
included
Participants Odds ratio [95% conﬁdence intervals] Statistical
signiﬁcance
Heterogeneity
(Higgins’ I2)
One-year survival
All 4 425 0.08 [0.01, 0.47]
† Signiﬁcant 75.1%
Three-year survival
All 9 938 0.15 [0.08, 0.26] Signiﬁcant 7.9%
Microscopic node involvement 3 232 0.24 [0.11, 0.55] Signiﬁcant 0%
Routine lymphadenectomy 7 832 0.13 [0.06, 0.28]
† Signiﬁcant 27.3%
Hepatoduodenal ligament only 3 430 0.24 [0.11, 0.55] Signiﬁcant 0%
Hepatic pedicle 4 402 0.20 [0.10, 0.39] Signiﬁcant 0%
Adjuvant chemotherapy 2 177 0.10 [0.01, 1.03]
† Not
signiﬁcant 63.5%
Published before 2000 7 622 0.09 [0.04, 0.18] Signiﬁcant 1.8%
Published after 2000 2 316 0.17 [0.05, 0.57]
† Signiﬁcant 46.1%
Five-year survival
All 7 904 0.10 [0.04, 0.27] Signiﬁcant 0%
Microscopic node involvement 2 220 0.14 [0.03, 0.72] Signiﬁcant 0%
Routine lymphadenectomy 6 810 0.09 [0.03, 0.24] Signiﬁcant 0%
Hepatoduodenal ligament only 3 430 0.09 [0.02, 0.38] Signiﬁcant 0%
Hepatic pedicle 3 380 0.08 [0.02, 0.34] Signiﬁcant 0%
Adjuvant chemotherapy 1 155 0.05 [0.00, 0.81] Signiﬁcant Not applicable
Published before 2000 5 588 0.09 [0.03, 0.29] Signiﬁcant 0%
Published after 2000 2 316 0.07 [0.01, 0.38] Signiﬁcant 0%
One-year disease-freesurvival
All 19 4 0.24 [0.05, 1.15] Not
signiﬁcant Not applicable
Three-year disease-freesurvival
All 19 4 0.10 [0.01, 1.78] Not
signiﬁcant Not applicable
Five-year disease-freesurvival
All 19 4 0.15 [0.01, 2.81] Not
signiﬁcant Not applicable
†Random-eﬀects model as there was statistical heterogeneity.
node and use of special techniques to identify microscopic
involvement [37].
There was signiﬁcant heterogeneity between the studies
in the one year survival with a 50% diﬀerence between the
study with maximum and that with minimum survival. This
is more likely to reﬂect diﬀerent criteria used for selecting
patients for “potentially curative resection” rather than sur-
gical techniques. In spite of the diﬀerence in the prevalence
of node-positive cases and the selection criteria, the data was
suitable for meta-analysis because of the lack of heterogene-
ity in most of the 3-year and 5-year survival comparisons.
No signiﬁcant diﬀerence was found in the proportion of
hepatic node-positive and node-negative patients who were
disease free at the end of one, three, and ﬁve years following
lymphadenectomy. This is surprising in view of the major
diﬀerence in survival and may reﬂect the small number of
patients in the node-positive category. Only one study [18]
reported this outcome.
The meta-analysis has clearly demonstrated that the sur-
vival rates are lower in patients with positive hepatic lymph
nodes compared to patients with negative lymph nodes, ir-
respective of whether the involvement was microscopic or
macroscopic and whether routine or selective lymphadenec-
tomy was carried out. The odds of 3-year survival in patients
with positive lymph nodes (draining the liver) were about
an eighth of the odds of survival in patients with negative
lymph nodes. This dropped even more to one twelfth for 5-
yearsurvivalinpatientswithpositivelymphnodescompared
to those with negative lymph nodes. Only 2 of the 151 pa-
tients with positive hepatic node were alive at 5 years.
Two studies [15, 35] compared survival in micro-
scopic involvement of hepatic pedicle (hepatoduodenal and8 HPB Surgery
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Figure 2
common hepatic artery group of nodes) having excluded
those who had macroscopic involvement). The survival was
signiﬁcantly lower in node-positive group compared to the
node-negative group. The 3-year and 5-year survival of mi-
croscopic node-positive patients were 20.5% and 3.2% com-
pared to 56.5% and 26.5% in microscopically node-negative
disease. Since the survival data on patients with macroscopic
diseaseisnotavailableseparately,itisnotclearwhetherthere
isasurvivaldiﬀerencebetweenmacroscopicandmicroscopic
hepatic lymph node involvement.
It is not clear from many studies whether the nodes with
macroscopic involvement were conﬁrmed histologically. The
study by Beckhurts et al.demonstrated that one third of the
nodes that appear to be macroscopically involved on imag-
ing (3 out of 9 patients with CT evidence of hepatic nodal
involvement) were found to be histologically negative for
metastatic spread [8]. Clearly, patients require histological
conﬁrmation of suspected nodal disease.
The 3-year survival and 5-year survival in positive hepa-
toduodenal ligament nodal status was 4.7% and 1.2% com-
pared to 3-year and 5-year survival rates of 11.3% and 1.5%
inpatientswithpositivehepaticpediclenodalstatus.Thelat-
ter group by deﬁnition includes the former group also. How-
ever, in the studies where the hepatic pedicle was dissected,
the survival data for patients with common hepatic artery
andcoeliacnodeinvolvementisnotavailableseparatelyfrom
thatofpatientswithhepatoduodenalligamentnodalinvolve-
ment. Whether involvement of common hepatic artery and
coeliac artery nodes carries a worse prognosis compared to
hepatoduodenal ligament nodal involvement has not been
established nor whether a more extensive lymphadenectomy
confers beneﬁt.
T h e r eh a v eb e e nn or a n d o m i z e dc o n t r o l l e dt r i a l sc o m -
paring liver resection alone with routine lymphadenectomy
or lymphadenectomy in those with macroscopically involved
nodes. Similarly, there have been no randomized controlled
trials comparing liver resection along with lymphadenec-
tomy with nonsurgical treatments such as chemotherapy in
patientswithnode-positivedisease,whowereotherwisesuit-
able for liver resection.Routine lymphadenectomy is being
performed to remove the microscopically involved nodes
draining the liver and provide cancer clearance. Although
none of the included studies reported any complication
speciﬁcally related to routine lymphadenectomy, it involves
removing additional structures. Radical lymphadenectomy
in patients with other gastrointestinal cancers has been
reported to be associated with increased morbidity [38].
None of the included studies compared the survival or re-
currence rates between those who underwent routine lym-
phadenectomy and selective lymphadenectomy (based on
ﬁnding macroscopic disease). However, the 5-year survival
ofnode-positive patients identiﬁed byroutinelymphadenec-
tomy is only 2/130, for example, 1.5%. Node-negative pa-
tients from the same cohort of patients who underwent
potentially curative liver resection had a 5-year survival of
29.9%. This suggests that node-positive disease had a major
impact on cancer recurrence.
Two of the included studies, involving patients who
underwent routine lymphadenectomy, used adjuvant
chemotherapy. The 3-year and 5-year survival in hepatic
node-positive patients in these two studies were 6.7% and
0%. In the study by Nakamura et al.[28], all the patients
in the study received chemotherapy. The 3-year survival in
the 6 patients with positive hepatic lymph node was 33.3%.
This study did not report the 5-year survival. The second
study which mentioned the chemotherapy was by Harms
et al.[29], in which chemotherapy was given in patients
with poor prognostic factors. The 3-year and 5-year survival
of hepatic node-positive cases in this study was 2.6% and
0%.There is currently no evidence of any beneﬁt of adjuvant
chemotherapy in the presence of nodal disease.
None of the studies considered the role for neo-adjuvant
chemotherapy. Recently, neo-adjuvant chemotherapy has
beenusedtodownstagepreviouslynon-resectablemetastatic
colorectal cancer (the reasons for nonresectability include
extra-hepaticdiseaseinthelungsandlymphnodes)withrea-
sonable three-year results [5, 39]. Preoperative chemother-
apy is being used in other node-positive tumours including
oesophageal cancers [40, 41] and rectal cancers [42, 43]f o r
downstaging the disease and may improve the median sur-
vival [40]. It is not clear whether neo-adjuvant chemother-
apy will be useful in improving the survival in people with
node-positive disease. The role of neo-adjuvant chemother-
apy in patients with colorectal liver metastases with hep-
atic node involvement needs to be evaluated in a prospective
trial. However, only people with macroscopic positive hep-
atic lymph nodes could be included in this trial. The in-
cidence of macroscopically positive hepatic lymph nodes is
4.8% in patients with otherwise resectable colorectal hepatic
metastases [8]. In order to demonstrate a 5% 3-year survival
beneﬁt (an additional 5% of people surviving at the end of
3 years with the control 3-year survival rate assumed to be
11.3%; see Table 3), the overall sample size required is 36 pa-
tients when the alpha and beta errors were set at 0.05 and
0.2. However, in such a study, there will a high percentage of
cross-over between the groups as patients, who progress in
spite of chemotherapy in the surgery group may no longer
be resectable. It may also be unethical to refuse surgery for
patients belonging to the chemotherapy group, whose dis-
ease has been down staged by chemotherapy. However, these
patients could be considered for a study involving surgical
resection for patients responding to systemic chemotherapy.Kurinchi S. Gurusamy et al. 9
A better 3-year survival in patients with nodal disease
was noted in the studies published after 2000 (8/40 = 20%)
compared to those published before 2000 (9/111 = 8.1%).
However, the 5-year survival in patients with nodal disease is
poor in both categories. It is possible that the improved ad-
juvant chemotherapy has an impact on survival in patients
with nodal disease.
From the results of our review, we conclude that there
is no evidence of survival beneﬁt for routine lymphadenec-
tomy from randomized controlled trials or from observa-
tionalstudiescomparingroutineandselectivelymphadenec-
tomy at the time of liver resection for colorectal liver metas-
tases.Patientswithenlargedhilarlymphnodesrequirehisto-
logical conﬁrmation of metastatic disease. Patients with con-
ﬁrmed hepatic node-positive status have a poor prognosis in
spite of resection with few 3-year survivors (11.3%). Survival
rates are low in patients with positive lymph nodes draining
the liver irrespective of whether they are detected by routine
lymphadenectomy or by macroscopic involvement. Patients
withresectableliver metastasesand combined hilarnodal in-
volvement could be considered for a study oﬀering surgical
resection(liverresectionandlymphadenectomy)forpatients
responding to systemic chemotherapy.
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